Diffuse large B-cell lymphoma is the most common aggressive subtype of non-Hodgkin lymphoma, and for decades its frontline treatment has been essentially unchanged: R-CHOP, a five-drug chemotherapy regimen built on CHOP, a regimen developed in the 1970s. On October 5, 2026, Genmab and AbbVie changed that calculus.
The companies announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed-duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with standard-of-care R-CHOP versus R-CHOP alone. The trial demonstrated a statistically significant improvement in progression-free survival, with the risk of disease progression or death reduced by 51% (HR 0.49; p-value < 0.0001). AbbVie and Genmab said EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate a statistically significant and clinically meaningful improvement in PFS in patients with frontline DLBCL.
That is not a narrow footnote. Cutting progression risk in half, in newly diagnosed patients, using a subcutaneous injection alongside existing chemotherapy, is the kind of data that rewrites treatment guidelines. Genmab and AbbVie said they will engage global regulatory authorities to determine next steps. The Genmab US ADR rose about 10.7% on Monday in response.
The Business Behind the Science
Most investors watching the stock move focused on the clinical milestone. The more durable question is structural: how does Genmab profit from this, and what does the model tell us about compounding value in biopharma?
Genmab does not run a global sales force. It builds antibodies, licenses them to well-capitalized partners, and collects royalties and milestone payments while the partner handles much of the commercial infrastructure. In 2020, Genmab entered into a collaboration agreement with AbbVie to jointly develop and commercialize epcoritamab, with the companies sharing commercialization responsibilities in the U.S. and Japan, and AbbVie responsible for further global commercialization. Under the terms of the agreement, AbbVie paid Genmab $750 million upfront, with potential for up to $3.15 billion in additional development, regulatory, and sales milestone payments, plus tiered royalties between 22% and 26% on net sales outside the U.S. and Japan.
The same architecture funds the rest of the business. Genmab’s projected 2026 revenue primarily consists of DARZALEX royalties of approximately $2.83 billion at the midpoint. DARZALEX is a daratumumab product licensed to Johnson & Johnson years ago. Genmab invented the molecule and has collected royalties ever since, without marketing a single vial itself.
In Q1 2026, royalties comprised 83% of Genmab’s revenue, with net product sales and collaboration revenue accounting for the remaining 15%. EPKINLY, the branded form of epcoritamab, posted $137 million in Q1 2026 sales, representing 52% year-over-year growth. That growth curve was built entirely in the relapsed and refractory setting. A frontline approval would open a significantly larger patient pool.
What Could Go Wrong
The enthusiasm deserves scrutiny. Epcoritamab plus R-CHOP remains investigational for frontline DLBCL and unapproved by any regulatory authority for that use. The Independent Data Monitoring Committee recommended unblinding the trial based on the interim analysis, which is a strong signal, but the full data set and regulatory submissions still lie ahead. Overall survival results were not reported in the topline readout, and regulators may weigh that gap carefully.
Competition in frontline DLBCL is also real. Polatuzumab vedotin plus R-CHP already has a foothold there, and CAR-T programs continue to push earlier in the treatment sequence. Frontline trials are actively testing R-CHOP combined with novel agents, CAR-T, and bispecific antibodies. Genmab’s data is the strongest bispecific result in this setting to date, but it will not go unchallenged.
Then there is valuation. Genmab updated its full-year 2026 revenue guidance to $4.325 to $4.525 billion before this trial readout. The stock’s Monday move prices in a meaningful share of the frontline opportunity already. Investors who missed the session are buying into expectations, not just biology.
The Long-Term Verdict
The EPCORE DLBCL-2 result matters beyond a single drug approval. It validates a platform. If a bispecific antibody can move this decisively into the frontline setting, the intellectual framework Genmab has built across its pipeline carries greater credibility. Charlie Munger famously admired businesses where the competitive advantages compound over time rather than erode. A royalty-generating antibody platform with multiple licensed programs, two of which now sit in frontline hematology, fits that description better than most.
The risk is binary: regulatory approval or not. The reward, if approval comes, is penetration of a frontline DLBCL market projected to reach $7.54 billion by 2030. Genmab does not need to capture all of it. It needs only to keep inventing molecules that partners fight to license.
